High priorities: sustainability & continual improvement
Actavis Completes Forest Laboratories Acquisition

Specialty R&D

An industry-leading pipeline with strong life cycle management strategies

Actavis’ branded pharmaceuticals business has an industry-leading pipeline of product opportunities focused on ensuring sustainable growth in each therapeutic category.

Our pipeline is driven by key opportunities to develop treatments for patients suffering from diseases in the central nervous system, gastroenterology, women’s health, urology, cardiovascular, respiratory and anti-infective therapeutic categories. We also have a portfolio of five biosimilar products under development in the Women’s Health and Oncology therapeutic categories.

Actavis focuses its business development efforts on finding new opportunities to invest in and adding additional products to the pipeline.

Actavis’ R&D strategy focuses on the following product development areas:

  • The application of proprietary drug-delivery technology for new product development in specialty areas
  • The acquisition of mid-to-late development-stage brand drugs and biosimilars

Our near-term product development pipeline includes 16 product candidates at the Phase III or NDA stages of development, including treatments for Alzheimer’s disease, cardiovascular disease, infectious disease, as well as treatments for Schizophrenia and bipolar disorders and treatments for COPD.